• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

配体结合的结构和动力学决定因素以及病理性激活剂 p25 和抑制肽 CIP 对细胞周期蛋白依赖性激酶 5 的调节作用。

Structural and dynamic determinants of ligand binding and regulation of cyclin-dependent kinase 5 by pathological activator p25 and inhibitory peptide CIP.

机构信息

Information Technology Laboratory, National Institute of Standards and Technology, Gaithersburg, MD 20899, USA.

出版信息

J Mol Biol. 2010 Aug 20;401(3):478-92. doi: 10.1016/j.jmb.2010.06.040. Epub 2010 Jun 25.

DOI:10.1016/j.jmb.2010.06.040
PMID:20599546
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2919306/
Abstract

The crystal structure of the cdk5/p25 complex has provided information on possible molecular mechanisms of the ligand binding, specificity, and regulation of the kinase. Comparative molecular dynamics simulations are reported here for physiological conditions. This study provides new insight on the mechanisms that modulate such processes, which may be exploited to control pathological activation by p25. The structural changes observed in the kinase are stabilized by a network of interactions involving highly conserved residues within the cyclin-dependent kinase (cdk) family. Collective motions of the proteins (cdk5, p25, and CIP) and their complexes are identified by principal component analysis, revealing two conformational states of the activation loop upon p25 complexation, which are absent in the uncomplexed kinase and not apparent from the crystal. Simulations of the uncomplexed inhibitor CIP show structural rearrangements and increased flexibility of the interfacial loop containing the critical residue E240, which becomes fully hydrated and available for interactions with one of several positively charged residues in the kinase. These changes provide a rationale for the observed high affinity and enhanced inhibitory action of CIP when compared to either p25 or the physiological activators of cdk5.

摘要

该 cdk5/p25 复合物的晶体结构提供了关于配体结合、特异性和激酶调节的可能分子机制的信息。这里报告了生理条件下的比较分子动力学模拟。这项研究为调节这些过程的机制提供了新的见解,这些机制可能被用来控制 p25 的病理性激活。在激酶中观察到的结构变化通过涉及细胞周期蛋白依赖性激酶(cdk)家族内高度保守残基的相互作用网络得到稳定。通过主成分分析鉴定了蛋白质(cdk5、p25 和 CIP)及其复合物的集体运动,揭示了 p25 复合物化后激活环的两种构象状态,在未复合的激酶中不存在,也不是晶体中明显的。未复合抑制剂 CIP 的模拟显示结构重排和包含关键残基 E240 的界面环的柔韧性增加,该残基完全水合并可与激酶中的几个正电荷残基之一相互作用。这些变化为 CIP 与 p25 或 cdk5 的生理激活剂相比表现出的高亲和力和增强的抑制作用提供了合理的解释。

相似文献

1
Structural and dynamic determinants of ligand binding and regulation of cyclin-dependent kinase 5 by pathological activator p25 and inhibitory peptide CIP.配体结合的结构和动力学决定因素以及病理性激活剂 p25 和抑制肽 CIP 对细胞周期蛋白依赖性激酶 5 的调节作用。
J Mol Biol. 2010 Aug 20;401(3):478-92. doi: 10.1016/j.jmb.2010.06.040. Epub 2010 Jun 25.
2
Evaluation of the interaction of cyclin-dependent kinase 5 with activator p25 and with p25-derived inhibitor CIP.细胞周期蛋白依赖性激酶5与激活剂p25及p25衍生抑制剂CIP相互作用的评估。
J Comput Biol. 2010 May;17(5):707-21. doi: 10.1089/cmb.2009.0202.
3
Explaining the inhibition of cyclin-dependent kinase 5 by peptides derived from p25 with molecular dynamics simulations and MM-PBSA.用分子动力学模拟和 MM-PBSA 解释源自 p25 的肽对周期蛋白依赖性激酶 5 的抑制作用。
J Mol Model. 2010 Jan;16(1):1-8. doi: 10.1007/s00894-009-0514-1. Epub 2009 May 23.
4
Different mechanisms of CDK5 and CDK2 activation as revealed by CDK5/p25 and CDK2/cyclin A dynamics.CDK5/p25和CDK2/细胞周期蛋白A动力学揭示的CDK5和CDK2激活的不同机制
J Biol Chem. 2006 Mar 17;281(11):7271-81. doi: 10.1074/jbc.M509699200. Epub 2006 Jan 9.
5
An in silico approach for the discovery of CDK5/p25 interaction inhibitors.一种用于发现 CDK5/p25 相互作用抑制剂的计算方法。
Biotechnol J. 2011 Jul;6(7):871-81. doi: 10.1002/biot.201100139. Epub 2011 Jun 16.
6
De Novo Rational Design of Peptide-Based Protein-Protein Inhibitors (Pep-PPIs) Approach by Mapping the Interaction Motifs of the PP Interface and Physicochemical Filtration: A Case on p25-Cdk5-Mediated Neurodegenerative Diseases.从头设计基于肽的蛋白质-蛋白质抑制剂(Pep-PPIs)的方法,通过映射 PP 界面的相互作用基序和物理化学过滤:以 p25-Cdk5 介导的神经退行性疾病为例。
J Cell Biochem. 2024 Sep;125(9):e30633. doi: 10.1002/jcb.30633. Epub 2024 Aug 15.
7
A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation.一段 24 个氨基酸残基的肽(p5),来源于 p35,是 Cdk5 神经元激活物,能特异性抑制 Cdk5-p25 的过度激活和 Tau 的过度磷酸化。
J Biol Chem. 2010 Oct 29;285(44):34202-12. doi: 10.1074/jbc.M110.134643. Epub 2010 Aug 18.
8
Structure and regulation of the CDK5-p25(nck5a) complex.CDK5-p25(nck5a)复合物的结构与调控
Mol Cell. 2001 Sep;8(3):657-69. doi: 10.1016/s1097-2765(01)00343-4.
9
Mechanism of CDK5/p25 binding by CDK inhibitors.CDK抑制剂与CDK5/p25结合的机制。
J Med Chem. 2005 Feb 10;48(3):671-9. doi: 10.1021/jm049323m.
10
Mechanism of CDK5 activation revealed by steered molecular dynamics simulations and energy calculations.定向分子动力学模拟和能量计算揭示的 CDK5 激活机制。
J Mol Model. 2010 Jun;16(6):1159-68. doi: 10.1007/s00894-009-0629-4. Epub 2009 Dec 15.

引用本文的文献

1
Molecular simulation-based investigation of thiazole derivatives as potential LasR inhibitors of Pseudomonas aeruginosa.基于分子模拟对噻唑衍生物作为铜绿假单胞菌潜在LasR抑制剂的研究。
PLoS One. 2025 Apr 22;20(4):e0320841. doi: 10.1371/journal.pone.0320841. eCollection 2025.
2
Multi-Target β-Protease Inhibitors from : In Silico and In Vitro Studies.来自[具体来源未给出]的多靶点β-蛋白酶抑制剂:计算机模拟和体外研究
Plants (Basel). 2019 Jul 17;8(7):231. doi: 10.3390/plants8070231.
3
The interaction of Munc 18 (p67) with the p10 domain of p35 protects in vivo Cdk5/p35 activity from inhibition by TFP5, a peptide derived from p35.

本文引用的文献

1
Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1.低分子量激活剂对蛋白激酶PDK1的结构及变构效应
Nat Chem Biol. 2009 Oct;5(10):758-64. doi: 10.1038/nchembio.208. Epub 2009 Aug 30.
2
Quantification and its applications in fluorescent microscopy imaging.荧光显微镜成像中的定量分析及其应用。
Traffic. 2009 Aug;10(8):951-61. doi: 10.1111/j.1600-0854.2009.00938.x. Epub 2009 May 5.
3
Explaining the inhibition of cyclin-dependent kinase 5 by peptides derived from p25 with molecular dynamics simulations and MM-PBSA.
Munc 18(p67)与p35的p10结构域之间的相互作用可在体内保护Cdk5/p35活性免受TFP5(一种源自p35的肽)的抑制。
Mol Biol Cell. 2016 Nov 1;27(21):3221-3232. doi: 10.1091/mbc.E15-12-0857. Epub 2016 Sep 14.
4
Computational study of the inhibitory mechanism of the kinase CDK5 hyperactivity by peptide p5 and derivation of a pharmacophore.肽p5对激酶CDK5过度活跃抑制机制的计算研究及药效团的推导
J Comput Aided Mol Des. 2016 Jun;30(6):513-21. doi: 10.1007/s10822-016-9922-3. Epub 2016 Jul 8.
5
Detection and characterization of nonspecific, sparsely populated binding modes in the early stages of complexation.络合早期非特异性、稀疏占据结合模式的检测与表征。
J Comput Chem. 2015 May 15;36(13):983-95. doi: 10.1002/jcc.23883. Epub 2015 Mar 18.
6
Consensus models for CDK5 inhibitors in silico and their application to inhibitor discovery.CDK5抑制剂的计算机模拟共识模型及其在抑制剂发现中的应用。
Mol Divers. 2015 Feb;19(1):149-62. doi: 10.1007/s11030-014-9561-3. Epub 2014 Dec 16.
7
Specific and non-specific protein association in solution: computation of solvent effects and prediction of first-encounter modes for efficient configurational bias Monte Carlo simulations.溶液中特异性和非特异性蛋白质的相互作用:溶剂效应的计算和首次遭遇模式的预测,以实现有效的构象偏差蒙特卡罗模拟。
J Phys Chem B. 2013 Oct 17;117(41):12360-74. doi: 10.1021/jp4050594. Epub 2013 Oct 7.
8
Mechanism of displacement of a catalytically essential loop from the active site of mammalian fructose-1,6-bisphosphatase.催化关键环从哺乳动物果糖-1,6-二磷酸酶活性部位的位移机制。
Biochemistry. 2013 Aug 6;52(31):5206-16. doi: 10.1021/bi400532n. Epub 2013 Jul 24.
9
Molecular dynamic simulations give insight into the mechanism of binding between 2-aminothiazole inhibitors and CDK5.分子动力学模拟深入了解 2-氨基噻唑抑制剂与 CDK5 之间结合的机制。
J Mol Model. 2013 Jun;19(6):2635-45. doi: 10.1007/s00894-013-1815-y. Epub 2013 Mar 23.
用分子动力学模拟和 MM-PBSA 解释源自 p25 的肽对周期蛋白依赖性激酶 5 的抑制作用。
J Mol Model. 2010 Jan;16(1):1-8. doi: 10.1007/s00894-009-0514-1. Epub 2009 May 23.
4
CHARMM: the biomolecular simulation program.CHARMM:生物分子模拟程序。
J Comput Chem. 2009 Jul 30;30(10):1545-614. doi: 10.1002/jcc.21287.
5
Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease.微管相关蛋白tau的过度磷酸化:阿尔茨海默病一个有前景的治疗靶点。
Curr Med Chem. 2008;15(23):2321-8. doi: 10.2174/092986708785909111.
6
Cdk5 phosphorylates PLD2 to mediate EGF-dependent insulin secretion.细胞周期蛋白依赖性激酶5使磷脂酶D2磷酸化,以介导表皮生长因子依赖性胰岛素分泌。
Cell Signal. 2008 Oct;20(10):1787-94. doi: 10.1016/j.cellsig.2008.06.009. Epub 2008 Jun 25.
7
Ab initio computational modeling of loops in G-protein-coupled receptors: lessons from the crystal structure of rhodopsin.G蛋白偶联受体中环状结构的从头算计算建模:来自视紫红质晶体结构的经验教训。
Proteins. 2006 Aug 15;64(3):673-90. doi: 10.1002/prot.21022.
8
Scalable molecular dynamics with NAMD.使用 NAMD 的可扩展分子动力学
J Comput Chem. 2005 Dec;26(16):1781-802. doi: 10.1002/jcc.20289.
9
Recent evidence regarding a role for Cdk5 dysregulation in Alzheimer's disease.近期关于细胞周期蛋白依赖性激酶5(Cdk5)失调在阿尔茨海默病中作用的证据。
Curr Alzheimer Res. 2004 Feb;1(1):33-8. doi: 10.2174/1567205043480519.
10
Mechanism of CDK5/p25 binding by CDK inhibitors.CDK抑制剂与CDK5/p25结合的机制。
J Med Chem. 2005 Feb 10;48(3):671-9. doi: 10.1021/jm049323m.